Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company specializing in the development and commercialization of life-transforming therapies for patients with rare and ultra-rare diseases. The company generates revenue primarily through the sale of its flagship product, Soliris, which treats conditions like paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Founded in 1992, Alexion has a significant history of innovation in complement biology and has expanded its portfolio through strategic acquisitions, including the purchase of Achillion Pharmaceuticals in 2020.

Recent Posts by Alexion Pharmaceuticals

1-20 of 543